23 November 2021>: Original Paper
The Future Direction of the Organ Donation System After Legislation of the Life-Sustaining Treatment Decision Act
Seung Min Baik 1BCEF , Jin Park 2BF , Tae Yoon Kim 3BF , Jung Hwa Lee 4BF , Kyung Sook Hong 3ACD*DOI: 10.12659/AOT.934345
Ann Transplant 2021; 26:e934345
Table 1 Demographics and disease characteristics of patients who agreed to discontinue life-sustaining treatment.
Variables | n=442 (%) |
---|---|
Sex, Male | 238 (53.8%) |
Mean age (years) | 71.8±14.0 |
From 0 to 9 | 0 |
From 10 to 19 | 0 |
From 20 to 29 | 2 (0.5%) |
From 30 to 39 | 7 (1.6%) |
From 40 to 49 | 21 (4.8%) |
From 50 to 59 | 56 (12.7%) |
From 60 to 69 | 86 (19.5%) |
From 70 to 79 | 106 (24.0%) |
From 80 to 89 | 138 (31.2) |
From 90 to 99 | 25 (5.7%) |
From 100 | 1 (0.2%) |
Type of Life-sustaining treatment decision | |
Self-decision | 110 (24.9%) |
Decision by family | 332 (75.1%) |
Admitted department | |
Hemato-oncology | 102 (23.1%) |
Pulmonology | 74 (16.7%) |
Neurosurgery | 56 (12.7%) |
Gastroenterology | 44 (10.0%) |
Neurology | 40 (9.0%) |
Surgery | 40 (9.0%) |
Cardiology | 19 (4.3%) |
Nephrology | 19 (4.3%) |
Urology | 14 (3.2%) |
Obstetrics & Gynecology | 12 (2.7%) |
Emergency medicine | 8 (1.8%) |
Etc. | 14 (3.2%) |
Diagnosis | |
Malignancy | 218 (49.3%) |
CNS disease | 93 (21.0%) |
Neither malignancy or nor CNS disease | 131 (29.6%) |
CNS – central nervous system. |